TESTOSTERONE CYCLOPENTYLPROPIONATE
testosterone 17B-cypionate
CAS: 58-20-8
Molecular Formula: C27H40O3
TESTOSTERONE CYCLOPENTYLPROPIONATE - Names and Identifiers
| Name | testosterone 17B-cypionate |
| Synonyms | T-Ionate-P.A Testosterone cypionate TESTOSTERONE CYPIONATE 1-Testosterone Cypionate testosterone 17B-cypionate TESTOSTERONE 17BETA-CYPIONATE TESTOSTERONE CYCLOPENTYLPROPIONATE TESTOSTERONE CYCLOPENTANE PROPIONATE testosterone17β-cyclopentylpropionate TESTOSTERONE 17BETA-CYCLOPENTANEPROPIONATE 17-(Cyclopentyl-1-oxopropoxy)androst-4-en-3-one 3-oxoandrost-4-en-17-yl 3-cyclopentylpropanoate (17beta)-3-oxoandrost-4-en-17-yl 3-cyclopentylpropanoate |
| CAS | 58-20-8 |
| EINECS | 200-368-4 |
| InChI | InChI=1/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1 |
| InChIKey | HPFVBGJFAYZEBE-ZLQWOROUSA-N |
TESTOSTERONE CYCLOPENTYLPROPIONATE - Physico-chemical Properties
| Molecular Formula | C27H40O3 |
| Molar Mass | 412.6 |
| Density | 0.9795 (rough estimate) |
| Melting Point | 101-102° |
| Boling Point | 492.01°C (rough estimate) |
| Specific Rotation(α) | D25 +87° (CHCl3) |
| Flash Point | 223.9°C |
| Vapor Presure | 3.78E-11mmHg at 25°C |
| Storage Condition | 2-8°C |
| Refractive Index | 1.5460 (estimate) |
TESTOSTERONE CYCLOPENTYLPROPIONATE - Risk and Safety
| Hazard Symbols | T - Toxic |
| Risk Codes | R45 - May cause cancer R63 - Possible risk of harm to the unborn child |
| Safety Description | S53 - Avoid exposure - obtain special instructions before use. S22 - Do not breathe dust. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
| WGK Germany | 3 |
| RTECS | XA3066000 |
| HS Code | 2937290000 |
TESTOSTERONE CYCLOPENTYLPROPIONATE - Reference Information
| NIST chemical information | Information provided by: webbook.nist.gov (external link) |
| Pharmacological effects | Endogenous androgens are responsible for the normal growth and development of male sexual organs and maintain secondary sexual characteristics, including the growth and maturation of prostate, seminal vesicle, penis and scrotum; development of male hair distribution, such as beard, pubic bone, chest and axillary hair; enlargement of larynx, thickening of vocal cords, and changes in body muscles and fat distribution. These drugs can also cause nitrogen, sodium, potassium and cadmium to retain phosphorus and reduce urinary calcium excretion. Androgen has been reported to increase protein anabolism and decrease protein catabolism. Androgen is responsible for puberty and the final growth spurt to terminate linear growth, caused by fusion of epiphyseal growth centers. In children, exogenous androgens accelerate the linear growth rate, but may lead to disproportionate progress in bone maturation. Prolonged use may lead to fusion of epiphyseal growth centers and termination of growth processes. It is reported that androgens produce erythropoiesis stimulating factors by enhancing the production of stimulating erythrocytes. During the administration of exogenous androgens, endogenous testosterone release is inhibited by feedback inhibition of pituitary luteinizing hormone (LH). |
| Pharmacokinetics | Testosterone cyclopentanpropionate is less polar than free testosterone, and the testosterone ester in the injected oil is slowly absorbed from the lipid stage in the muscle; therefore, Testosterone cyclopropionate can be given every two to four weeks. Testosterone in plasma binds to specific testosterone-estradiol with 98% binding globulin, and about 2% is free. In general, the amount of binding of this sex hormone The globulin in the plasma will determine the distribution of testosterone between free and testosterone, and the concentration of free testosterone will determine its half-life. About 90% of the dose of testosterone is excreted in the urine in the combined form of glucuronic acid and glucose; about 6% of the dose is excreted in the stool, mostly in unbound form. The inactivation of testosterone is mainly in the liver. Testosterone is metabolized into various 17-keto sterols through two pathways. When injected intramuscularly, the half-life of testosterone cyclopropionate is about eight days. |
| Indications | 1. Primary hypogonadism (congenital or acquired): cryptorchidism due to testicular failure, bilateral torsion, orchitis, testicular disappearance syndrome; Or orchiectomy. 2. Hypogonadism (congenital or acquired): Gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury caused by tumor, trauma or radiation. |
Last Update：2024-04-09 19:05:09
Supplier List
Spot supply
Product Name: Testosteronecypionate Visit Supplier Webpage Request for quotationCAS: 58-20-8
Tel: +86 0571-86722205
Email: sales@chinaskyrun.com
Mobile: +8618958170122
QQ: 2531159185
Wechat: chinaskyrun
Spot supply
Product Name: Testosteronecypionate Visit Supplier Webpage Request for quotationCAS: 58-20-8
Tel: +86 0571-86722205
Email: sales@chinaskyrun.com
Mobile: +8618958170122
QQ: 2531159185
Wechat: chinaskyrun
View History